Blue Light Versus White Light Surgery for High-Risk Bladder Cancer
Compares blue-light and white-light scoping to remove bladder tumors in adults.
Plain-language title generated from the registry record
Registry title: Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
Key facts
- Where
- Baltimore and Washington D.C., United StatesSee the 2 sites
- Phase
- Phase 3
Where in United States
- Johns Hopkins University School Of MedicineBaltimore, United StatesTaking people
- Sibley Memorial HospitalWashington D.C., United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Johns Hopkins University
- Trial code
- NCT06525571
- Record updated
- 3 November 2026
- Original description
Comparing white-light cystoscopy (WLC) and blue-light cystoscopy (BLC) in TURBT for high risk (HR) non-muscle invasive bladder cancer (NMIBC) patients is crucial to determine the most effective method for reducing residual disease burden and improving recurrence-free survival. Enhanced visualization with BLC may lead to more accurate resections, potentially decreasing recurrence rates and improving long-term outcomes for bladder cancer patients. Patients will be randomized to either WLC TURBT or BLC TURBT, and outcomes will be measured using standard-of-care testing with cystoscopy and cytology, along with minimal residual disease (MRD) burden evaluation using urine next-generation sequencing.Read full original descriptionShow less
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
Comparing white-light cystoscopy (WLC) and blue-light cystoscopy (BLC) in TURBT for high risk (HR) non-muscle invasive bladder cancer (NMIBC) patients is crucial to determine the most effective method for reducing residual disease burden and improving recurrence-free survival. Enhanced visualization with BLC may lead to more accurate resections, potentially decreasing recurrence rates and improving long-term outcomes for bladder cancer patients. Patients will be randomized to either WLC TURBT or BLC TURBT, and outcomes will be measured using standard-of-care testing with cystoscopy and cytology, along with minimal residual disease (MRD) burden evaluation using urine next-generation sequencing.
Inclusion: Patients undergoing TURBT for radiographic or cystoscopic positive tumor; 18+ years old; Upper tract evaluated using standard of care throughout duration of the study; Induction intravesical therapy initiated within four weeks of TURBT.
Exclusion: Prior history of pelvic radiation; History, or current diagnosis, of upper tract tumor or muscle-invasive bladder cancer; Active urinary tract infection (UTI); Variant histology consisting of less than 50% urothelial carcinoma; Patients who are noncompliant with the study protocol.